GONGWINBIOPHARM

Gongwin Biopharm Holdings, Co., Ltd. Cayman (Gongwin-KY; ticker: 6617) founded in 2014 is a Taiwan-based clinical-stage biopharmaceutical company focused on developing novel anti-cancer drugs. We adopt an innovative anti-tumor therapy called "minimally-invasive targeted tumor ablation" (MITTA) therapy for the treatment of focal malignancies. In 2017, Gongwin-KY has been granted "Biotech New Drug Company" designation by MOEA, Taiwan and became a public trading company at Taipei Emerging Stock Board... To leverage Taiwan's research and development capabilities and deploy our global business strategy, PTS International Inc., in 2014, established Gongwin Biopharm Holdings Co., Ltd. Cayman and Gongwin Biopharm Co., Ltd. in Taiwan and completed re-organization in December 2015. Gongwin Biopharm Co., Ltd., the wholly-owned subsidiary of Gongwin Biopharm Holdings Co., Ltd. Cayman, is the global business headquarter responsible for new drug development, clinical study, manufacturing,..

Also known as: Gongwin Biopharm Co., Ltd., Gongwin Biopharm Holdings, Co., Ltd.